Gennecs Pharmaceuticals is establishing a multi-vaccine production facility, GennVax, in Egypt in addition to launching a vaccine research center with a total investment of $150 million.
Gennecs will produce vaccines that are in line with Egypt’s national immunization program, such as: HPV, polio, hepatitis A and B, among others. The GennVax facility received accreditation from the World Health Organization (WHO).
The pharmaceutical company told Enterprise in an interview, that both projects are in partnership with investors from Saudi Arabia and the UAE and that the factory will be able to produce 300 million vaccines yearly.
If you see something out of place or would like to contribute to this story, check out our Ethics and Policy section.